HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

FR 173657

structure given in first source
Also Known As:
(E)-3-((6-acetamido-3-pyridyl)-N-(N-(2,4-dichloro-3-((2-methyl-8-quinolinyl)oxymethyl)phenyl)-N-methyl) aminocarbonyl methyl)acrylamide; FR-173657; FR173657
Networked: 26 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Morishita, Yasuo: 4 articles (01/2005 - 09/2002)
2. Totsuka, Osamu: 4 articles (01/2005 - 09/2002)
3. Matsumoto, Koshi: 4 articles (01/2005 - 09/2002)
4. Takeyoshi, Izumi: 4 articles (01/2005 - 09/2002)
5. Hayashi, Izumi: 3 articles (03/2009 - 03/2002)
6. Majima, Masataka: 3 articles (03/2009 - 03/2002)
7. Ohwada, Susumu: 3 articles (11/2004 - 09/2002)
8. Hashimoto, Naoki: 3 articles (11/2004 - 09/2002)
9. Tokumine, Masahiko: 3 articles (11/2004 - 09/2002)
10. Sunose, Yutaka: 3 articles (11/2004 - 09/2002)

Related Diseases

1. Reperfusion Injury
2. Ischemia
3. Tics (Tic)
01/01/2003 - "The B(2) receptor antagonists FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N [N-2-4-dichloro-3-[(2-methyl-8-quinolinyl) oxymethyl] phenyl]-N-methylamino-carbonyl-ethyl] acrylamide) and Hoe 140 (D-Arg(0)-[Hyp(3), Thi(5), D-Tic(7), Oic(8)]-bradykinin produced a graded shift to the right associated with marked inhibition of the bradykinin-induced contraction. "
01/01/2002 - "As the specific peptide antagonist D-Arg-[Hyp(3),Thi(5),D-Tic(7),Oic(8)]-bradykinin (HOE140), (E)-3-(6-acetamido-3-pyridil)-N-[-N-[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxymethyl]phenyl]-N-methylaminocarbonylmethyl]acrylamide (FR173657) and 1-[[3-[2,4-dimethylquinolin-8-yl)oxymethyl] - 2,4 - dichloro - phenyl]sulfonyl] - 2(S) - [[4-[4-(aminoiminomethyl)-phenylcarbonyl]piperazin-1-yl]carbonyl]pyrrolidine (LF16-0335C) exhibited a high affinity for this receptor with K(i) values of 7.34+/-2.45 nM and 8.54+/-1.55 nM respectively. "
12/01/2000 - "This study examined the mitogenic effects of bradykinin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), the peptide bradykinin B(2) receptor antagonist Hoe 140 (D-Arg(0)[Hyp(3)-Thi(6)-D-Tic(7)-Oic(8)]BK, and the orally active, nonpeptide B(2) receptor antagonist FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-2-4-dichloro-3-[(2-methyl-8-quino linyl) oxymethyl]phenyl]-N-methylaminocarbonyl-methyl]acrylamide) in three different human tumour cell lines: the small cell lung carcinoma (SCLC) cell line H-69, the breast carcinoma cell line EFM-192A, and the colon carcinoma cell line SW-480. "
4. Small Cell Lung Carcinoma (Small Cell Lung Cancer)
5. Carcinoma (Carcinomatosis)

Related Drugs and Biologics

1. Bradykinin B2 Receptor
2. Bradykinin
3. 2,5-dichloro-4-bromophenol (B 2)
4. icatibant
5. 2- ((3- (1,3- benzodioxol- 5- yl)- 3- (((6- methoxy- 2- naphthyl)sulfonyl)amino)propanoyl)amino)- 3- (4- ((2,6- dimethylpiperidinyl)methyl)phenyl)- N- isopropyl- N- methylpropanamide
6. Kinins
7. Enalapril
8. Carrageenan
9. Antigens
10. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1. Lung Transplantation
2. Oral Administration